Pharmaceutical Executive-08-01-2017

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

Experts assess the current pharma dealmaking landscape-one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.

Four strategic takeaways from this year's that are important for pharma oncology leaders.

Pharm Exec’s 13th Annual Press Audit audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.

As more states approve the use of medical marijuana-and its rising profile as potential opioid alternative-industry and FDA are stepping up their focus on developing cannabis-derived therapies.

For the life sciences industry in 2017, engaging across social media means less talking-and more listening.

The growing toll requires new assessment of risks, expanded provider education, and more scrutiny of marketed products.

Outlining the new communication priorities necessary to excel in the emerging outcomes-based healthcare landscape.

How artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.

Indonesia, once considered by global investors as Asia’s “greatest underachiever,” is showing signs of an economic resurgence, nowhere more apparent than in the country’s pharmaceuticals sector.

Click the title above to open the Pharmaceutical Executive August 2017 issue in an interactive PDF format.